Thursday, April 08, 2021 10:36:44 AM
USRM needs to establish the difference between tissue manipulation via SVF and the creation of a drug. In the case of SVF, they need to prove tissue manipulation does not qualify the product as a drug simply because the process involves separating stem cells from fat where the end product – tissue remnant – is unchanged from its natural state. This is no different than intra-operative autologous blood transfusions which requires manipulation (as I have said earlier) where red blood cells are isolated from other blood products then scrubbed clean before returning to the patient via transfusion. The machine used to carry out the procedure is FDA approved, but the blood (tissue) products are not.
The underlying question here is who should have regulatory authority over stem cell tissue transplant procedures? The FDA claims to have the legal authority. But if the procedures can be reclassified as tissue manipulation without synthesis then it should be no different than any other tissue transplant procedure where FDA regulation/guidance does not apply.
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONG • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM